[go: up one dir, main page]

PE20081578A1 - Formulacion en polvo de valganciclovir - Google Patents

Formulacion en polvo de valganciclovir

Info

Publication number
PE20081578A1
PE20081578A1 PE2007001774A PE2007001774A PE20081578A1 PE 20081578 A1 PE20081578 A1 PE 20081578A1 PE 2007001774 A PE2007001774 A PE 2007001774A PE 2007001774 A PE2007001774 A PE 2007001774A PE 20081578 A1 PE20081578 A1 PE 20081578A1
Authority
PE
Peru
Prior art keywords
amount
refers
dosage form
water
powder formulation
Prior art date
Application number
PE2007001774A
Other languages
English (en)
Inventor
Shah Navnit Hargovindas
Martin Howard Infeld
Maria Oksana Bachynsky
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39410167&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081578(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20081578A1 publication Critical patent/PE20081578A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

SE REFIERE A UNA FORMA DE DOSIFICACION FARMACEUTICA SOLIDA PARA ADMINISTRACION ORAL, DESPUES DE HABERSE CONSTITUIDO EN AGUA, QUE CONSTA DE: (a) UNA CANTIDAD TERAPEUTICA EFICAZ DE VALGANCICLOVIR CLORHIDRATO PRESENTE EN UNA CANTIDAD DE 10% AL 90% EN PESO DE LA COMPOSICION TOTAL; Y (b) UN ACIDO ORGANICO NO HIGROSCOPICO PRESENTE EN UNA CANTIDAD SUFICIENTE PARA ESTABILIZAR AL VANGANCICLOVIR CLORHIDRATO EN UNA CANTIDAD PREDETERMINADA DE AGUA, Y ADEMAS BAJE EL pH DE LA SOLUCION CONSTITUIDA HASTA UN pH DE 3.8 O MENOS, SIENDO SELECCIONADOS EL ACIDO FUMARICO, ACIDO SUCCINICO Y AC. ADIPICO. TAMBIEN SE REFIERE A UNA FORMA DE DOSIFICACION LIQUIDA. DICHA FORMULACION ES UTIL EN EL TRATAMIENTO O CONTROL DE VIRUS HERPES SIMPLEX Y EL CITOMEGALOVIRUS
PE2007001774A 2006-12-13 2007-12-12 Formulacion en polvo de valganciclovir PE20081578A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87463406P 2006-12-13 2006-12-13

Publications (1)

Publication Number Publication Date
PE20081578A1 true PE20081578A1 (es) 2008-11-12

Family

ID=39410167

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001774A PE20081578A1 (es) 2006-12-13 2007-12-12 Formulacion en polvo de valganciclovir

Country Status (31)

Country Link
US (6) US20080146591A1 (es)
EP (1) EP2101733B1 (es)
JP (1) JP5111517B2 (es)
KR (1) KR101116553B1 (es)
CN (1) CN101541310B (es)
AR (1) AR065541A1 (es)
AU (1) AU2007332640B2 (es)
BR (1) BRPI0720118B8 (es)
CA (1) CA2671470C (es)
CL (1) CL2007003564A1 (es)
CO (1) CO6220902A2 (es)
CR (1) CR10822A (es)
DK (1) DK2101733T3 (es)
ES (1) ES2391912T3 (es)
HR (1) HRP20121033T1 (es)
IL (1) IL198854A (es)
MA (1) MA31280B1 (es)
MX (1) MX2009005921A (es)
MY (1) MY152540A (es)
NO (1) NO339838B1 (es)
NZ (1) NZ577179A (es)
PE (1) PE20081578A1 (es)
PL (1) PL2101733T3 (es)
PT (1) PT2101733E (es)
RS (1) RS52457B (es)
RU (1) RU2440118C2 (es)
SI (1) SI2101733T1 (es)
TW (1) TWI341730B (es)
UA (1) UA93599C2 (es)
WO (1) WO2008071573A2 (es)
ZA (1) ZA200903840B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009221761A1 (en) * 2008-03-07 2009-09-11 Ray W. Exley Treatment of herpes virus related diseases
CN102048677B (zh) * 2009-11-09 2014-03-05 杭州赛利药物研究所有限公司 一种盐酸缬更昔洛韦固体制剂及其制备方法
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
JP6177879B2 (ja) * 2012-04-20 2017-08-09 アンジー ファーマスーティカル カンパニー リミテッドＡｎｎｊｉ Ｐｈａｒａｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． プリンアナログのシクロプロパンカルボキシレートエステル
EP2942052A4 (en) 2013-01-07 2016-06-08 Sam A Pharm Co Ltd NEW FORMULATION OF RAPID DISSOLUTION PELLETS WITH ENHANCED SOLUBILITY
EP3027215B1 (en) * 2013-08-02 2017-05-03 Ali Raif Ilaç Sanayi ve Ticaret Anonim Sirketi Powder formulation of valganciclovir
CN104055746B (zh) * 2014-07-12 2017-06-30 河北仁合益康药业有限公司 一种盐酸缬更昔洛韦包衣片剂组合物
RU2720805C1 (ru) * 2019-05-22 2020-05-13 Общество с ограниченной ответственностью "Трейдсервис" Фармацевтическая композиция валганцикловира
EP3976198A4 (en) 2019-05-31 2023-07-19 Viracta Subsidiary, Inc. METHODS OF TREATMENT OF VIRAL ASSOCIATED CANCER WITH HISTONE DEACETYLASE INHIBITORS
CN110613718A (zh) * 2019-09-19 2019-12-27 湖北科益药业股份有限公司 一种缬更昔洛韦组合物
CN110934823B (zh) * 2019-12-27 2022-03-01 湖北康源药业有限公司 一种盐酸缬更昔洛韦口服溶液及制备方法
WO2021161317A1 (en) * 2020-02-12 2021-08-19 Cts Chemical Industries Ltd. Stable pharmaceutical compositions comprising valgancyclovir and uses thereof
CN114028347B (zh) * 2021-11-30 2023-05-12 海南皇隆制药股份有限公司 注射用帕瑞昔布钠及其制备方法
CN115569113B (zh) * 2022-09-19 2023-11-10 江苏汉晨药业有限公司 一种盐酸缬更昔洛韦口服溶液

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880002139B1 (ko) 1983-04-08 1988-10-17 베링거 인겔하임 리미티드 경구 투여용 정제의 제조방법
US6083953A (en) 1994-07-28 2000-07-04 Syntex (U.S.A.) Inc. 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative
US5840890A (en) 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
EP1017372A4 (en) * 1997-10-03 2006-05-24 Smithkline Beecham Corp SOLID GALENIC FORMS WITH CONTROLLED LITHIUM CARBONATE RELEASE
US6221917B1 (en) * 1997-12-30 2001-04-24 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
CA2244097A1 (en) * 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
US20020143058A1 (en) * 2001-01-24 2002-10-03 Taro Pharmaceutical Inductries Ltd. Process for preparing non-hygroscopic sodium valproate composition
ES2297067T3 (es) 2003-03-19 2008-05-01 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Composiciones farmaceuticas no higroscopicas que contienen acidos quinolinacarboxilicos de hidratados.
CN1860120A (zh) * 2003-08-28 2006-11-08 兰贝克赛实验室有限公司 无定形盐酸缬更昔洛韦
EP1725217B1 (en) * 2004-03-10 2008-08-06 Ranbaxy Laboratories, Ltd. Processes for the preparation of solid dosage forms of amorphous valganciclovir hydrochloride
RU2442574C2 (ru) 2005-08-22 2012-02-20 Новартис Аг ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ pН-ЗАВИСИМОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, МОДИФИКАТОР pН И ЗАМЕДЛЯЮЩИЙ АГЕНТ

Also Published As

Publication number Publication date
CA2671470C (en) 2012-05-01
ZA200903840B (en) 2010-03-31
JP5111517B2 (ja) 2013-01-09
CL2007003564A1 (es) 2008-07-18
IL198854A0 (en) 2010-02-17
US8889109B2 (en) 2014-11-18
RS52457B (sr) 2013-02-28
US20180153998A1 (en) 2018-06-07
PT2101733E (pt) 2012-10-30
UA93599C2 (en) 2011-02-25
US20170266286A1 (en) 2017-09-21
DK2101733T3 (da) 2013-02-04
US20080146591A1 (en) 2008-06-19
RU2009126616A (ru) 2011-01-20
MY152540A (en) 2014-10-15
AU2007332640A1 (en) 2008-06-19
US20130150382A1 (en) 2013-06-13
MA31280B1 (fr) 2010-04-01
NO20092254L (no) 2009-07-09
CR10822A (es) 2009-06-25
US20190117775A1 (en) 2019-04-25
AU2007332640B2 (en) 2011-04-07
CA2671470A1 (en) 2008-06-19
KR101116553B1 (ko) 2012-03-13
RU2440118C2 (ru) 2012-01-20
WO2008071573A3 (en) 2008-11-27
TWI341730B (en) 2011-05-11
US9642911B2 (en) 2017-05-09
BRPI0720118B1 (pt) 2020-11-17
AR065541A1 (es) 2009-06-17
IL198854A (en) 2014-06-30
PL2101733T3 (pl) 2013-02-28
EP2101733B1 (en) 2012-09-26
HRP20121033T1 (hr) 2013-01-31
CO6220902A2 (es) 2010-11-19
JP2010513237A (ja) 2010-04-30
NO339838B1 (no) 2017-02-06
US20150057296A1 (en) 2015-02-26
EP2101733A2 (en) 2009-09-23
BRPI0720118B8 (pt) 2021-05-25
ES2391912T3 (es) 2012-12-03
KR20090086469A (ko) 2009-08-12
NZ577179A (en) 2011-12-22
CN101541310A (zh) 2009-09-23
US11185588B2 (en) 2021-11-30
WO2008071573A2 (en) 2008-06-19
MX2009005921A (es) 2009-06-17
BRPI0720118A2 (pt) 2014-01-14
SI2101733T1 (sl) 2012-12-31
TW200840585A (en) 2008-10-16
CN101541310B (zh) 2012-11-07

Similar Documents

Publication Publication Date Title
PE20081578A1 (es) Formulacion en polvo de valganciclovir
WO2013003629A3 (en) Methods and compositions for inhibition of bone resorption
EA201891154A1 (ru) Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
HRP20180425T1 (hr) Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
AR071187A1 (es) Compuesto de arilmetil-tiazinamina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento de la enfermedad de alzheimer
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
BR112015018168A2 (pt) inibidores de rock suaves
BRPI0924183B8 (pt) inibidores de cdk4/6 quinase, seus usos e sua forma cristalina iii, e formulação farmacêutica
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
AR075204A1 (es) Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
EA201290026A1 (ru) Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
PH12012502438A1 (en) Morpholino pyrimidines and their use in therapy
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
CL2008000750A1 (es) Metodo para la administracion de una dosis semanal de 2-[6-(3-amino-piperidin-1-il)3-metil-2,4 dioxo-3,4 dihidro-2h-pirimidin-1-il metil]-4 fluoro-benzonitrilo; composicion farmaceutica de una forma de dosificacion individual de dicho compuesto; y su
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
HRP20160327T1 (hr) Čvrsti dozirni oblici fentanila s poboljšanom bukalnom apsorpcijom
MX388825B (es) Uso y dosificacion de agentes terapeuticos para endometriosis.
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed